BMO Capital Maintains Outperform on Y-mAbs Therapeutics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout maintains an Outperform rating on Y-mAbs Therapeutics (NASDAQ:YMAB) but lowers the price target from $26 to $25.
August 13, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital analyst Etzer Darout maintains an Outperform rating on Y-mAbs Therapeutics but lowers the price target from $26 to $25.
The Outperform rating suggests continued confidence in the stock, but the lowered price target indicates a slight reduction in expected upside. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100